BioInvent International AB (publ) (STO:BINV)
22.50
+0.30 (1.35%)
Jul 24, 2026, 4:32 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 13.42M SEK in the quarter ending March 31, 2026, a decrease of -39.15%. This brings the company's revenue in the last twelve months to 217.86M, up 258.30% year-over-year. In the year 2025, BioInvent International AB had annual revenue of 226.50M with 406.86% growth.
Revenue (ttm)
217.86M
Revenue Growth
+258.30%
P/S Ratio
6.71
Revenue / Employee
1.95M
Employees
112
Market Cap
1.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 226.50M | 181.81M | 406.86% |
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
| Dec 31, 2018 | 38.55M | -6.47M | -14.36% |
| Dec 31, 2017 | 45.01M | -26.27M | -36.85% |
| Dec 31, 2016 | 71.28M | 55.36M | 347.62% |
| Dec 31, 2015 | 15.93M | -31.01M | -66.07% |
| Dec 31, 2014 | 46.93M | -34.78M | -42.56% |
| Dec 31, 2013 | 81.71M | 38.77M | 90.27% |
| Dec 31, 2012 | 42.95M | -81.70M | -65.55% |
| Dec 31, 2011 | 124.65M | 41.78M | 50.42% |
| Dec 31, 2010 | 82.87M | 2.21M | 2.74% |
| Dec 31, 2009 | 80.66M | -171.48M | -68.01% |
| Dec 31, 2008 | 252.14M | 108.70M | 75.78% |
| Dec 31, 2007 | 143.44M | 92.61M | 182.20% |
| Dec 31, 2006 | 50.83M | 22.63M | 80.26% |
| Dec 31, 2005 | 28.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 429.29M |
| Hansa Biopharma AB | 189.46M |
| Genovis AB (publ.) | 131.09M |
| Egetis Therapeutics AB | 63.10M |
| Medivir AB | 9.01M |
| Vicore Pharma Holding AB | 3.53M |
| Xspray Pharma AB | 2.47M |
| Infant Bacterial Therapeutics AB | -1.00K |
BioInvent International AB News
- 7 days ago - BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 - Accesswire
- 6 weeks ago - BioInvent International AB Transcript: KOL event - Transcripts
- 6 weeks ago - BioInvent International AB Press release: KOL event - Filings
- 6 weeks ago - BioInvent International AB Slides: KOL event - Filings
- 6 weeks ago - BioInvent International AB Transcript: Aktiedagarna 2026 - Transcripts
- 7 weeks ago - BioInvent International AB Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - BioInvent International: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology - Finanz Nachrichten
- 2 months ago - BioInvent International AB Transcript: KOL event - Transcripts